References
- US Department of Health and Human Services. Press release: HHS acting secretary declares public health emergency to address national opioid crisis. https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-publichealth-emergency-address-national-opioid-crisis.html. Published October 26, 2017. Accessed February 7, 2021.
- Center for Behavioral Health Statistics and Quality (CBHSQ). 2017 National survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
- U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder; 2020. Treatment Improvement Protocol TIP 63. Publication No. PEP20-02-01-006.
- Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2018.
- CDC. Vital statistics rapid release. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed November 4, 2021.
- CDC. Age-adjusted rates of drug overdose deaths involving opioids, by type of opioid: United States, 1999–2019. https://www.cdc.gov/nchs/data/databriefs/db394-tables-508.pdf#page=3. Accessed November 4, 2021.
- US Department of Justice. Press release: Department of Justice Announces DEA Seizures of Historic Amounts of Deadly Fentanyl-Laced Fake Pills in Public Safety Surge to Protect U.S. Communities. https://www.justice.gov/opa/pr/department-justice-announces-dea-seizures-historic-amounts-deadly-fentanyl-laced-fake-pills. Published September 30, 2021. Accessed November 4, 2021.
- Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6. doi:10.1097/MLR.0000000000000625
- The White House. Executive Office of the President. Office of National Drug Control Policy. 2022 National Drug Control Strategy. https://www.whitehouse.gov/wp-content/uploads/2022/04/National-Drug-Control-2022Strategy.pdf. Accessed July1, 2022.
- American Medical Association. 2021 overdose epidemic report. https://end-overdose-epidemic.org/. Accessed November 4, 2021.
- Ardeljan LD, Waldfogel JM, Bicket MC, Hunsberger JB, Vecchione TM, Arwood N, Eid A, Hatfield LA, McNamara L, Duncan R, et al. Current state of opioid stewardship. Am J Health Syst Pharm. 2020;77(8):636–43. doi:10.1093/ajhp/zxaa027
- The Society of Hospital Medicine. Reducing adverse drug events related to opioids, or RADEO implementation guide 2015. https://www.hospitalmedicine.org/globalassets/clinical-topics/clinical-pdf/shm_reducingopiodevents_guide.pdf. Accessed February 7, 2021.
- Kane-Gill SL, Rubin EC, Smithburger PL, Buckley MS, Dasta JF. The cost of opioid-related adverse drug events. J Pain Palliat Care Pharmacother. 2014;28(3):282–93. doi:10.3109/15360288.2014.938889
- Jarzyna D, Jungquist CR, Pasero C, Willens JS, Nisbet A, Oakes L, Dempsey SJ, Santangelo D, Polomano RC. American society for pain management nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118–45.e10. doi:10.1016/j.pmn.2011.06.008
- Pasero C, Quinlan-Colwell A, Rae D, Broglio K, Drew D, et al. American society for pain management nursing position statement: prescribing and administering opioid doses based solely on pain intensity. Pain Manag Nurs. 2016;17(3):170–80. doi:10.1016/j.pmn.2016.03.001
- Michigan Department of Health and Human Services. Michigan safer opioid prescribing toolkit. https://injurycenter.umich.edu/opioid-overdose/michigan-safer-opioid-prescribing-toolkit/. Accessed November 4, 2021.
- Hill M, McMahon ML, Stucke RS, Barth RJ.Jr. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg. 2017;265(4):709–14. doi:10.1097/SLA.0000000000001993
- Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066–71. doi:10.1001/jamasurg.2017.0831
- Schirle L, Stone AL, Morris MC, Osmundson SS, Walker PD, Dietrich MS, Bruehl S. Leftover opioids following adult surgical procedures: a systematic review and meta-analysis. Syst Rev. 2020;9(1):139. doi:10.1186/s13643-020-01393-8
- Brummett C, Steiger R, Englesbe M, et al. Effect of an activated charcoal bag on disposal of unused opioids after an outpatient surgical procedure a randomized clinical trial. AMA Surg. 2019;154(6):558–61.
- Barreveld AM, McCarthy RJ, Elkassabany N, Mariano ER, Sites B, Ghosh R, Buvanendran A. Opioid stewardship program and postoperative adverse events. Anesthesiology. 2020;132(6):1558–68. doi:10.1097/ALN.0000000000003238
- Lee JS, Howard RA, Klueh MP, Englesbe MJ, Waljee JF, Brummett CM, Sabel MS, Dossett LA. The impact of education and prescribing guidelines on opioid prescribing for breast and melanoma procedures. Ann Surg Oncol. 2019;26(1):17–24. doi:10.1245/s10434-018-6772-3
- Coulson E, Kral L. The clinical pharmacist’s role in perioperative surgical pain management. J Pain Palliat Care Pharmacother. 2020;34(3):120–6. doi:10.1080/15360288.2020.1734141
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49. doi:10.15585/mmwr.rr6501e1
- Dowell D, Compton WM, Giroir BP. Patient-centered reduction or discontinuation of long-term opioid analgesics: the HHS guide for clinicians. JAMA. 2019;322(19):1855–6. doi:10.1001/jama.2019.16409
- Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411–9. doi:10.1001/jama.2021.11013
- FDA Drug Safety Communication. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Published 2019. Accessed November 6, 2022.
- National Quality Forum. National quality partners playbook TM: opioid stewardship. NQF, Washington, DC. https://store.qualityforum.org/products/national-qualitypartners-playbookTM-opioid-stewardship. Published March 2018. Accessed February 7, 2021.
- Oddis J. Report of the ASHP opioid task force. Am J Health Syst Pharm. 2020;77:1158–65.
- The Joint Commission. Pain assessment and management standards for hospitals. R3 report. 37(11). https://www.jointcommission.org/assets/1/18/R3_Report_Issue_11_Pain_Assessment_2_9_18_REV_FINAL.pdf. Published August 2017. Accessed February 7, 2021.
- American Hospital Association. Stem the tide: opioid stewardship measurement implementation guide. Chicago, IL. www.aha.org/opioids. Published 2020. Accessed February 7, 2021.
- Substance Abuse and Mental Health Services Administration (SAMHSA) Website. Buprenorphine. https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine. Accessed May 20, 2021.
- Madras B, Ahmad N, Wen J, et al. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. https://nam.edu/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-key-barriers-within-the-treatment-system/. Accessed November 9, 2021.
- IQVIA Xponent limited to retail pharmacy dispensed prescriptions. Definition: USC 78312 Opioid Reversal Agents (naloxone) and USC 78340 Drug Dependence (buprenorphine and buprenorphine/naloxone), excludes buprenorphine indicated for pain management (USC 02200). 2012–2021.
- O'Donoghue AL, Biswas N, Dechen T, Anderson TS, Talmor N, Punnamaraju A, Stevens JP. Trends in filled naloxone prescriptions before and during the COVID-19 pandemic in the United States. JAMA Health Forum. 2021;2(5):e210393. doi:10.1001/jamahealthforum.2021.0393
- Centers for Disease Control and Prevention. Federal grantees may now use funds to purchase fentanyl test strips [press release]. Published April 7, 2021. https://www.cdc.gov/media/releases/2021/p0407-Fentanyl-Test-Strips.html. Accessed July 1, 2022.
- Goodlev ER, Discala S, Darnall BD, Hanson M, Petok A, Silverman M. Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorders: a team-based, interdisciplinary approach to cancer survivorship. J Palliat Med. 2019;22(11):1308–17. doi:10.1089/jpm.2019.0171
- National Academies of Sciences, Engineering, and Medicine. 2017. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Academies Press.
- Uritsky T, Michelle B, Chae S. Opioid stewardship: building on antibiotic stewardship principles. J Pain Pall Care Pharm. 2020;34:181–3. doi:10.1080/15360288.2020.1765066. Accessed February 7, 2021.
- Pedersen CA, Schneider PJ, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing—2019. Am J Health Syst Pharm. 2020;77(13):1026–50. doi:10.1093/ajhp/zxaa104
- Phelps P, Achey TS, Mieure KD, Cuellar L, MacMaster H, Pecho R, Ghafoor V. A survey of opioid medication stewardship practices at academic medical centers. Hosp Pharm. 2019;54(1):57–62. doi:10.1177/0018578718779005
- Poirier RH, Brown CS, Baggenstos YT, Walden SG, Gann NY, Patty CM, Sandoval RA, McNulty JR. Impact of a pharmacist-directed pain management service on inpatient opioid use, pain control, and patient safety. Am J Health Syst Pharm. 2019;76(1):17–25. doi:10.1093/ajhp/zxy003
- Veterans Health Administration. Pain management, opioid safety, and PDMP (PMOP). https://www.va.gov/PAINMANAGEMENT/PMOP/index.asp. Accessed November 6, 2022.
- Fudin J, Raouf M, Wegrzyn EL, Schatman ME. Safety concerns with the Centers for Disease Control opioid calculator. J Pain Res. 2013;11:1–4. https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/evaluation-comparison-online-equianalgesic-opioid-dose-conversion. doi:10.2147/JPR.S155444
- Shaw K, Fudin J. Evaluation and comparison of online equianalgesic opioid dose conversion calculators. Practical Pain Manag. 2013;13(7):61–6. Accessed April 30, 2022.
- Hewes HA, Dai M, Mann NC, Baca T, Taillac P. Prehospital pain management: disparity by age and race. Prehosp Emerg Care. 2018;22(2):189–97. doi:10.1080/10903127.2017.1367444
- Morales M, Yong RJ. Racial and ethnic disparities in the treatment of chronic pain. Pain Med. 2021;22(1):75–90. doi:10.1093/pm/pnaa427
- Weiner SG, Price CN, Atalay AJ, Harry EM, Pabo EA, Patel R, Suzuki J, Anderson S, Ashley SW, Kachalia A, et al. A health system-wide initiative to decrease opioid-related morbidity and mortality. Jt Comm J Qual Patient Saf. 2019;45(1):3–13. doi:10.1016/j.jcjq.2018.07.003
- Brandt N, Worz C, Clackum S. Expanding opportunities in the postacute long-term care setting: bringing medication safety to the next level. Pharmacotherapy. 2018;38(8):862–6. doi:10.1002/phar.2155
- Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm. 2019;76(7):424–35. doi:10.1093/ajhp/zxy089
- Genord C, Frost T, Eid D. Opioid exit plan: a pharmacist’s role in managing acute postoperative pain. J Am Pharm Assoc (2003). 2017;57(2):S92–8.
- Gondora N, Sanyal C, Carter C, et al. The role of pharmacists in opioid stewardship. Protocol. Res Soc Admin Pharm. 2020;17:993–6. doi:10.1016/j.sapharm.2020.06.027.Accessed November 9, 2021.
- Kominek C. Retrospective chart review of advanced practice pharmacist prescribing of controlled substances for pain management at the Harry S. Truman Memorial Veterans’ Hospital. Fed Pract. 2021;38(1):20–7. doi:10.12788/fp.0079
- Voll P, Brooks A, Vartan CM, DiScala S. Pharmacist interventions in an outpatient pain clinic at a Veterans Affairs Medical Center. J Am Coll Clin Pharm. 2022;5(2):149–56. doi:10.1002/jac5.1548
- Oregon State University [homepage on the Internet]. Corvallis: Academic Success Center. https://success.oregonstate.edu/learning/smart-goals. Accessed May 12, 2022.
- Faley B, Brooks A, Vartan C, DiScala S. Impact of clinical pharmacist practitioner-driven high opioid dose reevaluation in veterans with chronic non-cancer pain. J Pain Palliat Care Pharmacother. 2022;1–11. doi:10.1080/15360288.2022.2113594
- Ghafoor VL, Phelps P, Pastor J. Implementation of pain medication stewardship program. Am J Health-Syst Pharm. 2013;70(23):2070–5. doi:10.2146/ajhp120751
- Tanzi M. Pharmacists have lead role in hospital-based opioid stewardship programs. Pharmacy Today. Health-System Edition. October 2019. doi:10.1016/j.ptdy.2019.09.028
- Bratberg JP, Smothers ZPW, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ, et al. Pharmacists and the opioid crisis: a narrative review of pharmacists’ practice roles. J Am Coll Clin Pharm. 2020;3(2):478–84. doi:10.1002/jac5.1171
- Topham D, Drew D. Quality improvement project: replacing the numeric rating scale with a clinically aligned pain assessment (CAPA) tool. Pain Manag Nurs. 2017;18(6):363–71. doi:10.1016/j.pmn.2017.07.001
- Woods B, Legal M, Shalansky S, Mihic T, Ma W, et al. Designing a pharmacist opioid safety and intervention tool. Can J Hosp Pharm. 2020;73(1):7–12.
- Oyler D, Short R, Goree J. Quality indicators for opioid stewardship. Am J Health Syst Pharm. 2019;76(19):1457–8. doi:10.1093/ajhp/zxz162
- Rizk E, Swan JT, Cheon O, Colavecchia AC, Bui LN, Kash BA, Chokshi SP, Chen H, Johnson ML, Liebl MG, et al. Quality indicators to measure the effect of opioid stewardship interventions in hospital and emergency department settings. Am J Health Syst Pharm. 2019;76(4):225–35. doi:10.1093/ajhp/zxy042
- Jacobs SC, Son EK, Tat C, Chiao P, Dulay M, Ludwig A. Implementing an opioid risk assessment telephone clinic: outcomes from a pharmacist-led initiative in a large Veterans Health Administration primary care clinic, December 15, 2014–March 31, 2015. Subst Abus. 2016;37(1):15–9. doi:10.1080/08897077.2015.1129527
- Haley DF, Saitz R. The opioid epidemic during the COVID-19 pandemic. JAMA. 2020;324(16):1615–7. doi:10.1001/jama.2020.18543
- Hikma Pharmaceuticals. Hikma announces US FDA approval of KLOXXADO TM (naloxone hydrochloride) nasal spray 8mg [news release]. https://www.hikma.com/newsroom/article-i5120-hikma-announces-us-fda-approval-of-kloxxado-tm-naloxone-hydrochloride-nasal-spray-8mg/. Published April 30, 2021. Accessed May 1, 2022.
- Department of Health and Human Services. Centers for Medicare & Medicaid Services. 2021 updates to the child and adult core health care quality measurement sets. https://www.medicaid.gov/federal-policy-guidance/downloads/cib111920.pdf. Accessed November 9, 2021.
- Fitzgerald Jones K, Khodyakov D, Arnold R, Bulls H, Dao E, Kapo J, Meier D, Paice J, Liebschutz J, Ritchie C, et al. Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder. JAMA Oncol. 2022;8(8):1107. doi:10.1001/jamaoncol.2022.2191
- Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the society of hospital medicine. J Hosp Med. 2018;13(4):263–71. doi:10.12788/jhm.2980
- Shoemaker-Hunt S, Wyant B. The effect of opioid stewardship interventions on key outcomes: a systematic review. J Patient Saf. 2020;16(3S Suppl 1):S36–S41. doi:10.1097/PTS.0000000000000710